How much will retatrutide cost?

Retatrutide has no official price because it is not yet FDA-approved. Based on Eli Lilly's pricing for tirzepatide (Zepbound at ~$1,060/mo list) and retatrutide's superior efficacy (28.7% weight loss), analysts project a list price of $1,000-1,500/mo. LillyDirect cash pricing could reduce this to $299-449/mo, similar to the Zepbound model.

Will insurance cover retatrutide?

Insurance coverage cannot begin until after FDA approval, which is projected for mid-to-late 2027. Even after approval, formulary negotiations typically take 3-12 months. Retatrutide may initially be positioned as a step-therapy option after tirzepatide, meaning insurers could require patients to try tirzepatide first.

Will Medicare cover retatrutide?

Medicare coverage for GLP-1 medications for obesity is expanding in 2026. The Medicare GLP-1 Bridge program ($50/mo copay) is scheduled to launch July 1, 2026, covering approved GLP-1s for weight management. Retatrutide would need separate formulary negotiation after FDA approval and would likely be added post-approval.

Will there be a retatrutide savings card?

Eli Lilly has offered savings cards for both Mounjaro and Zepbound that reduced commercially insured patients' costs to as low as $25/mo. A similar savings card program for retatrutide is widely expected at launch, though specific terms have not been announced.

Is retatrutide cheaper than tirzepatide?

Retatrutide is projected to cost the same as or more than tirzepatide due to its superior efficacy (28.7% vs 20.9% weight loss). Tirzepatide currently costs ~$1,060/mo list price or $299/mo through LillyDirect. Orforglipron, Lilly's oral GLP-1 candidate, is expected at $149/mo pending FDA approval (PDUFA April 10, 2026).

Can I buy retatrutide now?

No. Retatrutide is not FDA-approved and cannot be legally obtained through any pharmacy, telehealth provider, or compounding pharmacy. Research peptide versions sold online are unregulated, unverified, and carry serious safety risks. We strongly advise waiting for the FDA-approved product.

Patient Guides

Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?

Updated March 28, 2026

Fact Checked

No official pricing exists for retatrutide — it hasn't been FDA-approved. Based on Lilly's existing portfolio, expect a list price of $1,000-1,500/mo with LillyDirect pricing potentially reducing that to $299-449/mo. Here's what we know, what we can project, and how to prepare.

Key Takeaways

No official retatrutide pricing exists — it is not FDA-approved; approval is projected mid-to-late 2027.
Analysts project a list price of $1,000-1,500/month based on Lilly's tirzepatide pricing of ~$1,060/month.
LillyDirect cash pricing for retatrutide is estimated at $299-449/month, modeled on the Zepbound program.
A Lilly savings card reducing commercially insured costs to ~$25/month is widely expected at launch.
Medicare coverage via the GLP-1 Bridge program ($50/month copay) would require separate formulary negotiation.

On this page

Find your match

Answer a few questions and we’ll match you with the right provider and medication.

Take the Quiz →

Free · 2 min · No signup required

Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?

Retatrutide is not FDA-approved. No official pricing exists. Everything in this guide is a projection based on publicly available data — Eli Lilly's existing pricing strategies, the competitive obesity drug market, and analyst estimates. Actual pricing will only be confirmed when Lilly announces commercial terms, which will not happen until closer to a potential approval date.

That said, retatrutide is the most anticipated obesity medication in development. It produced 28.7% weight loss in TRIUMPH-4 — the highest ever recorded in a Phase 3 trial — and patients are understandably asking what it will cost. This guide walks through what we can reasonably estimate and how to prepare financially for its potential launch.

For clinical details about retatrutide, see our retatrutide complete guide. For side effect data, see the retatrutide side effects guide. For dosing information, see the retatrutide dosing guide.

Where Things Stand: Timeline and Approval Status

Before discussing cost, the timeline matters — because it determines when any of these prices become relevant.

Current status: Retatrutide is in Phase 3 clinical trials (the TRIUMPH program)
NDA submission: Expected late 2026 or Q1 2027
FDA review: Standard review takes 10-12 months; Priority Review could shorten this to 6 months
Projected approval: Mid-to-late 2027 at the earliest
Pharmacy availability: 1-3 months after approval
Insurance coverage: 3-12 months after approval (varies widely by payer)

This means the earliest most patients could fill a retatrutide prescription is late 2027 or early 2028. Insurance coverage could lag well into 2028 for many plans.

The Research Peptide Market: A Warning

Search for "retatrutide cost" today and you will find research peptide vendors selling what they claim is retatrutide for $150-500 per month. We need to be direct about this.

We do not recommend, endorse, or link to any gray market or research peptide source for retatrutide. These products are:

Not manufactured under pharmaceutical-grade GMP conditions
Not verified for purity, potency, or sterility by the FDA
Not the same compound used in TRIUMPH clinical trials
Not legal to sell for human use

The FDA has not approved retatrutide for any indication. Any website claiming to sell it for weight loss is operating outside FDA regulations. The safety data from TRIUMPH trials applies only to the pharmaceutical-grade compound manufactured by Eli Lilly — not to research peptides of unknown provenance.

If you are considering treatment now, there are multiple FDA-approved GLP-1 medications available through legitimate telehealth providers and pharmacies. See our most affordable GLP-1 options guide for current pricing.

Projected FDA-Approved Pricing

While Lilly has not disclosed pricing, we can build a reasonable estimate from three reference points in Lilly's existing obesity portfolio.

Reference Point 1: Tirzepatide (Mounjaro/Zepbound)

Tirzepatide is retatrutide's closest comparable — a peptide injection from the same manufacturer, targeting a similar patient population.

List price: ~$1,060/month
LillyDirect price: $299/month (cash pay, no insurance)
With Lilly savings card: As low as $25/month for commercially insured patients
Mean weight loss: 20.9% at the highest dose (72 weeks)

Reference Point 2: Orforglipron

Lilly's oral GLP-1, launched at an aggressive price point to compete before broad insurance coverage.

Cash price: $149/month
No savings card needed: Priced as a cash-pay product from day one
Mean weight loss: 11.2% at the highest dose (72 weeks)

Reference Point 3: The Competitive Landscape

Novo Nordisk's semaglutide (Wegovy) has a list price of ~$1,350/month, though real-world costs vary. CagriSema pricing has not been announced.

Our Projection for Retatrutide

Given these data points, here is what we project:

Pricing Scenario	Estimated Monthly Cost	Basis
List price (WAC)	$1,000-1,500/mo	Premium over tirzepatide justified by superior efficacy
LillyDirect (cash pay)	$299-449/mo	Consistent with Lilly's direct-to-patient strategy
With Lilly savings card	$25-50/mo	Matches existing Mounjaro/Zepbound savings card terms
Medicare Part D (post-formulary)	$50-200/mo	Depends on plan tier and Medicare Bridge eligibility
Uninsured/no assistance	$1,000-1,500/mo	Full list price without any discount programs

Why $1,000-1,500 for the list price? Retatrutide's 28.7% weight loss represents a meaningful clinical improvement over tirzepatide's 20.9%. Lilly has strong incentive to price it at a premium. The triple-agonist mechanism (GLP-1/GIP/glucagon) is genuinely novel and could command premium positioning. However, Lilly also has to balance against three realities: competing with its own tirzepatide franchise, the growing political pressure on drug pricing, and the precedent set by orforglipron's $149 price point.

Why $299-449 through LillyDirect? Lilly has clearly signaled that LillyDirect is central to its obesity strategy. Zepbound through LillyDirect costs $299/month — a dramatic discount from the $1,060 list price. Lilly absorbs the difference to build patient volume and bypass PBM negotiations. Retatrutide would likely follow the same model, though the premium efficacy could justify a higher LillyDirect price than Zepbound.

These are estimates. Lilly could price retatrutide lower to maximize market share, or higher to position it as the premium option above tirzepatide. We will update this guide when official pricing is announced.

Lilly Savings Card: What to Expect

Eli Lilly has a strong track record with patient savings programs. Both Mounjaro and Zepbound launched with savings cards that dramatically reduced out-of-pocket costs for commercially insured patients.

What the Mounjaro/Zepbound savings cards offer:

Eligible commercially insured patients pay as little as $25/month
Available even when insurance does not cover the medication
Typical savings of $500-1,000 per fill
Annual cap on total savings (varies by program year)
Not available to patients with government insurance (Medicare, Medicaid, Tricare)

What we expect for retatrutide:

A savings card with similar structure is near-certain at launch. Lilly understands that insurance coverage will lag behind approval, and savings cards bridge that gap. For commercially insured patients, a retatrutide savings card could reduce monthly costs to $25-50 for the first 12-24 months after launch.

The key limitation: savings cards are not available to Medicare or Medicaid patients. For those populations, other pathways apply.

Medicare Coverage: The New Landscape

The Medicare landscape for obesity medications has changed significantly.

What Has Changed

Medicare Part D is expected to cover GLP-1 medications for obesity (Bridge program scheduled July 2026). Legislation passed in 2026 expanded Medicare drug coverage to include FDA-approved anti-obesity medications — ending years of exclusion that left Medicare patients paying full price or going without treatment.
The Medicare Bridge program is scheduled for July 2026. This program is expected to provide a $50/month copay for eligible Medicare patients using approved GLP-1 medications. It is expected to cover tirzepatide, semaglutide, and other FDA-approved options.

What This Means for Retatrutide

Retatrutide is not currently covered because it is not FDA-approved. After approval:

Medicare formulary negotiation must occur. CMS will negotiate retatrutide's placement on the Part D formulary. This process typically takes 3-6 months after approval.
Medicare Bridge eligibility is likely but not guaranteed. The program would need to add retatrutide to its covered drug list. Given the drug's clinical profile, inclusion is probable but will depend on CMS negotiations and budget impact.
Expected Medicare cost post-formulary: $50-200/month depending on plan tier, copay structure, and whether the Medicare Bridge program covers retatrutide.

For Medicare patients currently considering GLP-1 treatment: Do not wait for retatrutide. Multiple FDA-approved medications are available through Medicare Part D today, and the Medicare Bridge program can reduce costs to $50/month. See our retatrutide patient guide for the wait-vs-start analysis.

Insurance Coverage: Realistic Expectations

Commercial insurance coverage for retatrutide is uncertain, and the dynamics are more complex than usual because Lilly is competing with itself.

The Lilly Portfolio Problem

Lilly will have three obesity medications on the market:

Tirzepatide (Zepbound) — established, broad formulary coverage, $1,060 list
Orforglipron — oral, cheap ($149), increasingly covered
Retatrutide — highest efficacy, likely highest price

PBMs and insurers will likely structure coverage as a step therapy ladder: try orforglipron first (cheapest), then tirzepatide, then retatrutide only after inadequate response to the first two. This is standard payer behavior and Lilly is likely building its commercial strategy around it.

What This Means for Patients

If you have commercial insurance: Expect a prior authorization requirement and possible step therapy. Your insurer may require documented failure on tirzepatide before covering retatrutide.
If you are paying cash: LillyDirect pricing bypasses insurance entirely. This may be the fastest path to retatrutide at launch.
If you have a Lilly savings card: The card typically works even when insurance denies coverage, reducing cash price to savings card levels.

When Coverage Might Begin

Based on precedent from tirzepatide and orforglipron launches:

Coverage Type	Expected Timeline Post-Approval
LillyDirect (cash pay)	At launch
Lilly savings card	At launch
Major commercial insurers (some plans)	3-6 months
Broad commercial coverage	6-12 months
Medicare Part D formulary	3-6 months
Medicaid (varies by state)	6-18 months

Cost Comparison: Retatrutide vs. Current Options

This table compares projected retatrutide costs against currently available medications. All prices reflect the most current publicly available data.

Medication	List Price	Best Cash Price	With Savings/Assistance	Mean Weight Loss	Route
Retatrutide (projected)	$1,000-1,500/mo	$299-449/mo (LillyDirect est.)	$25-50/mo (savings card est.)	28.7% (48 wk)	Weekly injection
Tirzepatide (Zepbound)	~$1,060/mo	$299/mo (LillyDirect)	$25/mo (savings card)	20.9% (72 wk)	Weekly injection
Orforglipron	$149/mo	$149/mo	$149/mo (already cash-priced)	11.2% (72 wk)	Daily pill
Semaglutide (Wegovy)	~$1,350/mo	~$675/mo (NovoCare)	Varies by program	14.9% (68 wk)	Weekly injection
CagriSema	TBD	TBD	TBD	25.3% (68 wk)	Weekly injection

Key takeaway: Retatrutide will almost certainly be the most expensive option at list price. But through LillyDirect and savings card programs, the real out-of-pocket cost for most patients could be comparable to what Zepbound patients pay today. The question is whether the additional ~8 percentage points of weight loss (28.7% vs 20.9%) justifies any premium over tirzepatide.

For a full breakdown of current medication costs and access pathways, see our GLP-1 medication comparison chart and most affordable GLP-1 options guide.

How to Save on Retatrutide When It Launches

Here is a practical checklist for patients planning to start retatrutide once it becomes available.

1. Check Clinical Trial Enrollment

The TRIUMPH program is still enrolling patients for some trials. Clinical trial participation provides the medication at no cost with close medical monitoring. Search ClinicalTrials.gov for "retatrutide" to find open enrollment sites. See our retatrutide complete guide for trial details.

2. Register for LillyDirect Updates

LillyDirect is Lilly's direct-to-patient pharmacy and telehealth platform. Signing up before launch means you will be notified as soon as retatrutide becomes available and can access LillyDirect pricing from day one.

3. Plan for the Lilly Savings Card

If you have commercial insurance (not Medicare, Medicaid, or Tricare), the savings card will likely be your best cost-reduction tool. These cards are typically available at launch and require registration on Lilly's website.

4. Talk to Your Insurer About Formulary Plans

Call your insurance plan's pharmacy benefits line and ask whether they have plans to cover retatrutide after FDA approval. Specifically ask about:

Whether step therapy will be required (trying tirzepatide first)
Prior authorization requirements
Expected formulary tier

Getting this information early helps you plan — and if step therapy is required, starting on tirzepatide now both improves your health and satisfies the step therapy requirement.

5. Explore Medicare Bridge (If Applicable)

If you are a Medicare patient, confirm your enrollment in a Part D plan that participates in the Medicare Bridge program. Contact Medicare at 1-800-MEDICARE to verify your plan's GLP-1 coverage and Bridge program eligibility.

6. Ask About Patient Assistance Programs

Eli Lilly operates the Lilly Cares Foundation, which provides free medications to qualifying low-income patients. Eligibility is based on income (typically below 400% of the federal poverty level) and lack of adequate insurance coverage. These programs are expected to extend to retatrutide after approval.

7. Consider Starting Treatment Now

If you need weight loss treatment today, do not wait 12-18+ months for retatrutide. Multiple effective options exist now at accessible price points — tirzepatide through LillyDirect at $299/month, oral Wegovy at $199-299/month, or semaglutide through various access programs. Orforglipron (expected at $149/month, awaiting FDA approval — PDUFA April 10, 2026) is anticipated to be available very soon. Starting now does not prevent switching to retatrutide later.

What Could Change These Projections

Several factors could push retatrutide's real-world cost higher or lower than our estimates:

Factors that could lower the price:

CagriSema launching at an aggressive price, forcing Lilly to compete
Political pressure on drug pricing intensifying before the 2028 election
Lilly prioritizing volume over margin to dominate the obesity market
Generic/biosimilar semaglutide entering the market, disrupting pricing norms

Factors that could raise the price:

Retatrutide receiving additional indications (NASH, heart failure) that expand the addressable market
Limited manufacturing capacity constraining supply at launch
Clinical data demonstrating cost-effectiveness that justifies premium pricing to payers
Weaker-than-expected competition from CagriSema

The Bottom Line

Retatrutide will almost certainly be the most effective obesity medication on the market when it launches. It will also likely be the most expensive at list price. But "list price" is not what most patients actually pay.

For commercially insured patients, a Lilly savings card could reduce costs to $25-50 per month. For cash-pay patients, LillyDirect pricing is projected at $299-449 per month. For Medicare patients, Part D coverage and the Bridge program should provide access at $50-200 per month — though timing will lag behind approval.

The most important cost calculation is not retatrutide's price tag — it is the cost of waiting. If you need GLP-1 treatment today, effective and affordable options exist right now. Starting treatment sooner means earlier health benefits, and you can always transition to retatrutide when it becomes available.

For help finding the most affordable GLP-1 option available today, see our most affordable GLP-1 options guide. For the clinical case on whether to wait for retatrutide or start now, see our retatrutide patient guide.

Disclosure: Telehealth Ally does not receive payments from Eli Lilly, Novo Nordisk, or any pharmaceutical manufacturer. Our coverage is editorially independent. Revenue never influences our assessments or recommendations.

Related Comparisons

CagriSema vs Retatrutide: The Next-Gen GLP-1 Showdown

Head-to-head comparison of CagriSema (22.7% weight loss) vs retatrutide (up to 24.2% in Phase 2) — two next-gen medications that could reshape obesity treatment. Mechanisms, trial data, timelines, and who should wait.

Retatrutide vs Tirzepatide: Same Manufacturer, Different Mechanisms — Complete Comparison

Head-to-head comparison of retatrutide (triple-agonist, 28.7% weight loss) vs tirzepatide (Zepbound/Mounjaro, 20.9%). Both from Eli Lilly. Mechanism, efficacy, side effects, pricing, and availability.

Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?

Key Takeaways

Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?

Where Things Stand: Timeline and Approval Status

The Research Peptide Market: A Warning

Projected FDA-Approved Pricing

Reference Point 1: Tirzepatide (Mounjaro/Zepbound)

Reference Point 2: Orforglipron

Reference Point 3: The Competitive Landscape

Our Projection for Retatrutide

Lilly Savings Card: What to Expect

Medicare Coverage: The New Landscape

What Has Changed

What This Means for Retatrutide

Insurance Coverage: Realistic Expectations

The Lilly Portfolio Problem

What This Means for Patients

When Coverage Might Begin

Cost Comparison: Retatrutide vs. Current Options

How to Save on Retatrutide When It Launches

1. Check Clinical Trial Enrollment

2. Register for LillyDirect Updates

3. Plan for the Lilly Savings Card

4. Talk to Your Insurer About Formulary Plans

5. Explore Medicare Bridge (If Applicable)

6. Ask About Patient Assistance Programs

7. Consider Starting Treatment Now

What Could Change These Projections

The Bottom Line

Related Comparisons

CagriSema vs Retatrutide: The Next-Gen GLP-1 Showdown

Retatrutide vs Tirzepatide: Same Manufacturer, Different Mechanisms — Complete Comparison

More Guides

Does Aetna Cover GLP-1 Medications? 2026 Coverage Guide

Aleniglipron: Structure Therapeutics' Oral GLP-1 — What Patients Need to Know

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

AOD-9604 for Weight Loss: Telehealth Providers Guide 2026

Best GLP-1 Medication 2026: Every Approved Option Ranked by Use Case

Which GLP-1 Has the Fewest Side Effects? A Medication-by-Medication Comparison

Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026

Best GLP-1 Pill Options in 2026: Oral Wegovy, Orforglipron & More

Best Oral GLP-1 Options 2026: Foundayo vs Rybelsus Complete Comparison

Best GLP-1 Under $200 Per Month: 2026 Budget Guide

Best GLP-1 Weight Loss Programs 2026: Every Major Provider Ranked

Best Growth Hormone Peptide Providers Online: 2026 Independent Comparison

Best Online HRT 2026: Telehealth Menopause Treatment Platforms Compared

Best Online TRT Clinics 2026: Telehealth Testosterone Replacement Compared

Best Oral GLP-1 Options in 2026: Every Pill Compared

Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care

Best Weight Loss Injection 2026: Wegovy HD, Zepbound, and Every Option Compared

Best Weight Loss Medication 2026: Every FDA-Approved Option Ranked

Does Blue Cross Blue Shield Cover GLP-1 Medications? 2026 Guide

Best BPC-157 Telehealth Providers 2026: Complete Guide

BPC-157 vs TB-500: Which Injury Recovery Peptide Is Right for You?

CagriSema Dosing Guide: Titration Schedule, Dose Steps & What to Expect

CagriSema Launch Day Patient Guide: What to Do Now That It's Here

CagriSema: The Semaglutide + Cagrilintide Combination — Patient Guide

CagriSema FDA Decision Guide: What to Expect and How to Prepare

CagriSema: What Patients Need to Know While the FDA Decision Drags On

CagriSema Side Effects: What Clinical Trials Show About Safety and Tolerability

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

CJC-1295 vs Ipamorelin: Complete Telehealth Comparison Guide 2026

CMS BALANCE Model Explained: Medicaid Obesity Care for 2026 and Beyond

Medicare GLP-1 Bridge Program: Implementation FAQ for Patients

Compounded GLP-1 Shutdown Timeline: From Shortage to Enforcement (2023–2026)

Is Compounded HRT Safe? What Patients Need to Know in 2026

Is Compounded Semaglutide Legal and Safe in 2026?

Compounded Tirzepatide 2026: What's Happening and What Patients Should Do

Contrave Guide 2026: How It Works, Weight Loss Results & How It Compares to GLP-1s

Does Insurance Cover GLP-1 Medications? Complete 2026 Guide

Does Insurance Cover Semaglutide? 2026 Coverage Guide

Does Medicare Cover Ozempic? What You Need to Know in 2026

Does Medicare Cover Wegovy? Complete 2026 Coverage Guide

DSIP (Delta Sleep-Inducing Peptide) Telehealth Providers Guide 2026

Enclomiphene vs TRT: What Is the Difference and Which Is Right for You?

Epitalon Longevity Peptide: Telehealth Providers Guide 2026

FDA Enforcement Actions: What Happened After April 2 — Company Responses, Market Impact, and Patient Guidance

FDA Enforcement Actions Against Telehealth Providers: The Complete Tracker

FDA GLP-1 Enforcement Actions Tracker: April 2026 Warning Letters and What Comes Next